- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01977820
Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria (SIGNAL)
January 24, 2018 updated by: BioMarin Pharmaceutical
A Multicenter, Double-Blind, Placebo-Controlled, Randomized, 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria
This is a Phase 2a multicenter, double-blind, placebo-controlled, randomized, 2-arm pilot trial designed to assess the effect of sapropterin on cognitive abilities in young adults with Phenylketonuria (PKU) over a 26-week treatment period.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bologna, Italy
- Research Site
-
-
-
-
-
Lausanne, Switzerland
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 29 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent given before any trial-related activities are carried out
- Women or men with documented PKU diagnosed by at least two phenylalanine levels equal or greater than 600 micromole per liter (mcmol/L)
- For women of childbearing potential: a negative urine pregnancy test is required at screening and willingness to use a highly effective method of contraception is required during the study and follow-up periods
- Aged greater than or equal to (>=) 18 to 29 years, inclusive
- Mean blood phenylalanine levels 600 to 1000 mcmol/L during 12 months preceding inclusion in the study. The mean should be calculated from at least 3 blood phenylalanine values over the last 12 months. Screening blood phenylalanine level can be one of these values. There should be at least one value dated between Month -12 and -6 before Screening and at least one value dated between Month -6 and Screening
- An intelligence quotient (IQ) score greater than or equal to 85, assessed a maximum of 2 years before screening with an age-appropriate Wechsler scale. If no IQ test result is available, IQ testing must be performed as part of Screening using an age-appropriate Wechsler scale before the subject can be included
- Subjects willing to comply with all study procedures, including willingness to continue current dietary recommendations during the whole trial duration
Exclusion Criteria:
- Subjects with tetrahydrobiopterin (BH4) deficiency
- Previous exposure to sapropterin or BH4 for greater than 30 days (or exposure to sapropterin or BH4 for less than or equal to 30 days but within the previous 6 months prior to Screening visit)
- Subjects who, according to the Investigator, will not be able to comply with study procedures and computerized neuropsychological testing
- Any significant illness which, according to the Investigator, might preclude participation in the study (including neurological disease, cardio-vascular disease, history of seizure, predisposition to convulsions, renal or hepatic insufficiency, and active malignancy)
- Any significant illness, medication or substance abuse which, according to the Investigator, might affect cognitive function and cognitive testing (for example, significant visual or motor impairment, history of major head trauma, history of stroke, alcoholism, drug dependency, psychological disorder requiring chronic use of psychotropic medications such as anxiolytics, antidepressants, antipsychotic medication, mood stabilizers, and hypnotics)
- Concomitant forbidden medication as described in the Kuvan® Summary of Product Characteristics, namely, inhibitors of dihydrofolate reductase (for example, methotrexate, trimethoprim), medications that are known to affect nitric oxide synthesis (for example, glyceryl trinitrate, isosorbide dinitrate, sodium nitroprusside, molsidomin, phosphodiesterase type 5 inhibitors, and minoxidil), and levodopa, as it may cause increased excitability and irritability
- Known hypersensitivity to sapropterin or any ingredients in the product's formulation, or to other approved or non-approved formulations of BH4
- Subjects who have undergone cognitive neuropsychological testing similar to that to be performed as part of this trial with the following time limits: tasks with limited practice effect performed in the last 6 months, and tasks with important practice effect (such as tasks involving development of strategies) performed in the year preceding inclusion in the trial. Whether a task falls into one or the other category is left to Investigator judgment
- Female subjects who are pregnant or in the lactation period
- Subjects currently participating to another clinical trial or who participated in a previous clinical trial within 30 days prior to screening
- Legal incapacity or limited legal capacity
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
|
Experimental: Sapropterin
|
Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Death and AEs Leading to Discontinuation
Time Frame: Screening up to 24 weeks + 4-week follow-up
|
An AE was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship.
A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
|
Screening up to 24 weeks + 4-week follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Responsible, BioMarin Pharmaceutical
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
November 1, 2014
Study Registration Dates
First Submitted
October 31, 2013
First Submitted That Met QC Criteria
October 31, 2013
First Posted (Estimate)
November 7, 2013
Study Record Updates
Last Update Posted (Actual)
February 22, 2018
Last Update Submitted That Met QC Criteria
January 24, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EMR 700773-004
- 2010-024311-13 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phenylketonuria
-
Vitaflo International, LtdUniversity College London HospitalsRecruiting
-
BioMarin PharmaceuticalRecruitingPhenylketonuria (PKU)United States, Germany, Italy
-
Nutricia ResearchCompleted
-
BioMarin PharmaceuticalActive, not recruiting
-
BioMarin PharmaceuticalCompletedPhenylketonuria (PKU)United States, Turkey, Canada, France, Germany, Italy, United Kingdom
-
Washington University School of MedicineUniversity of Missouri-Columbia; Northwestern University; Oregon Health and Science... and other collaboratorsTerminated
-
BioMarin PharmaceuticalRecruitingPhenylketonuria (PKU)United States
-
University of Southern CaliforniaBioMarin PharmaceuticalCompleted
-
Stanford UniversityBioMarin PharmaceuticalWithdrawnClassical Phenylketonuria(PKU)
-
University of ZurichCompletedPhenylketonuria (PKU) and HyperphenylalaninemiaSwitzerland
Clinical Trials on Sapropterin
-
University of California, San DiegoBioMarin PharmaceuticalWithdrawnBehavioral Manifestations of Lesch-Nyhan DiseaseUnited States
-
University of UtahBioMarin PharmaceuticalCompletedGTP Cyclohydrolase DeficiencyUnited States
-
Washington University School of MedicineUniversity of Missouri-Columbia; Northwestern University; Oregon Health and Science... and other collaboratorsTerminated
-
University of Missouri-ColumbiaBioMarin PharmaceuticalCompletedPhenylketonuriaUnited States
-
The University of Texas Health Science Center,...BioMarin PharmaceuticalTerminatedPhenylketonuria | HyperphenylalaninemiaUnited States
-
Universidade do PortoBioMarin Pharmaceutical; Centro Hospitalar do PortoCompleted
-
Providence VA Medical CenterBioMarin Pharmaceutical; LifespanCompletedHeart Failure | Cardiovascular DiseaseUnited States
-
Washington University School of MedicineUniversity of Missouri-Columbia; BioMarin PharmaceuticalCompleted
-
The Children's Health CouncilBioMarin PharmaceuticalCompleted
-
Fundacion Clinic per a la Recerca BiomédicaCompletedLiver Cirrhosis | Portal HypertensionSpain